Keyphrases
Overall Survival
100%
Metastatic Melanoma
100%
Surrogate Endpoint
100%
Meta-analysis of Randomized Controlled Trials
100%
Progression-free Survival
87%
Randomized Trial
37%
Dacarbazine
37%
Random Effects
37%
Hazard Ratio
25%
Phase II Trial
25%
Fixed Effects
25%
Control Arm
25%
Meta-analysis
12%
Treatment Regimen
12%
Strong Correlation
12%
Treatment Effect
12%
Treatment Type
12%
Follow-up Data
12%
Sensitivity Analysis
12%
Correlation Coefficient
12%
Vemurafenib
12%
Dabrafenib
12%
Treatment Standards
12%
Trial Size
12%
Overall Survival Benefit
12%
Ratio Estimate
12%
Pearson Correlation Coefficient
12%
Weighting Strategy
12%
Controlled Randomized Trial
12%
Meeting Abstracts
12%
Medicine and Dentistry
Overall Survival
100%
Meta-Analysis
100%
Randomized Controlled Trial
100%
Metastatic Melanoma
100%
Progression Free Survival
77%
Dacarbazine
33%
Hazard Ratio
22%
Arm
22%
Treatment Effect
11%
Vemurafenib
11%
Dabrafenib
11%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
100%
Randomized Controlled Trial
100%
Metastatic Melanoma
100%
Progression Free Survival
77%
Dacarbazine
33%
Vemurafenib
11%
Dabrafenib
11%
Agricultural and Biological Sciences
Biochemistry, Genetics and Molecular Biology